Docetaxel/Gemcitabine Administered Every Other Week as First-Line Treatment for Metastatic Breast Cancer: Final Results of a Phase II Trial

The combination of docetaxel/gemcitabine once every 2 weeks is active and well tolerated in patients with untreated advanced breast carcinoma. This chemotherapy regimen might be useful in advanced breast cancer when anthracycline combinations are not preferred, such as cases previously treated with adjuvant anthracycline chemotherapy.